HER2-low heterogeneity and its impact on benefit from trastuzumab deruxtecan in metastatic breast cancer

被引：0
|
作者：
Zou, Y. [1 ]
Deng, X. [1 ]
Xie, J. [1 ]
Zeng, Y. [2 ]
Jing, B. [1 ]
Fu, J. [1 ]
Jiang, Y. [1 ]
Tang, H. [1 ]
Liu, P. [1 ]
Xie, X. [1 ]
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Dept Breast Oncol, Guangzhou, Peoples R China
[2] Univ Michigan, Dept Stat, Ann Arbor, MI 48109 USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.059
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
37MO
引用
收藏
页码：S1418 / S1418
页数：1
相关论文
共 50 条
  • [41] Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer
    Nie, Tina
    Blair, Hannah A.
    TARGETED ONCOLOGY, 2023, 18 (03) : 463 - 470
  • [42] New approval: Trastuzumab-deruxtecan for metastatic breast cancer HER2+
    Minot-This, Marie-Sophie
    Bellesoeur, Audrey
    BULLETIN DU CANCER, 2021, 108 (09) : 783 - 784
  • [43] Approval study DESTINY-Breast04 convinces in new category trastuzumab-deruxtecan: First targeted therapy for metastatic HER2-low breast cancer
    Fessler, Beate
    BREAST CARE, 2023, 18 (02)
  • [44] Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer
    Tina Nie
    Hannah A. Blair
    Targeted Oncology, 2023, 18 : 463 - 470
  • [45] Impact of HER2 expression dynamics on the realworld activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE)
    Tarantino, Paolo
    Hughes, Melissa
    Kusmick, Ross
    Alder, Laura
    Pereslete, Alyssa
    Noteware, Laura
    Moore, Heather
    Van Swearingen, Amanda
    Li, Tianyu
    Gupta, Hersh
    Smith, Kalie
    Morganti, Stefania
    Files, Janet
    Sendrick, Kerry
    Buck, Simone
    Dillon, Deborah
    Jeselsohn, Rinath
    Li, Yvonne
    Cherniack, Andrew
    Prat, Aleix
    Chan, Nay Nwe Nyein
    Rimm, David
    Curigliano, Giuseppe
    Sammons, Sarah
    Anders, Carey
    Lin, Nancy
    Tolaney, Sara
    CANCER RESEARCH, 2024, 84 (09)
  • [46] Trastuzumab deruxtecan, its efficacy in patients with metastatic HER2-positive breast cancer: a systematic review
    Fernhandho, V.
    Jhoputri, C. Fricilia
    Julian, L.
    Kurniawan, A.
    Huang, I.
    ANNALS OF ONCOLOGY, 2024, 35 : S1337 - S1337
  • [47] Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastases
    Khatri, Vaseem M.
    Mestres-Villanueva, Mariella A.
    Yarlagadda, Sreenija
    Doniparthi, Ajay
    Smith, David B.
    Nakashima, Justyn Y.
    Bryant, John M.
    Zhao, Dekuang
    Upadhyay, Rituraj
    Mills, Matthew N.
    Oliver, Daniel E.
    Yu, Hsiang-Hsuan Michael
    Palmer, Joshua D.
    Williams, Nicole O.
    Mahtani, Reshma L.
    Ahluwalia, Manmeet S.
    Soliman, Hatem H.
    Han, Hyo S.
    Soyano, Aixa E.
    Kim, Youngchul
    Kotecha, Rupesh
    Beyer, Sasha J.
    Ahmed, Kamran A.
    NPJ BREAST CANCER, 2024, 10 (01)
  • [48] The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan
    Schreiber, Anna R.
    O'Bryant, Cindy L.
    Kabos, Peter
    Diamond, Jennifer R.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (10) : 1061 - 1069
  • [49] Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial
    Batista, M. Vaz
    Perez-Garcia, J. M.
    Cortez, P.
    Garrigos, L.
    Fernandez-Abad, M.
    Gion, M.
    Martinez-Bueno, A.
    Saavedra, C.
    Teruel, I.
    Fernandez-Ortega, A.
    Servitja, S.
    Ruiz-Borrego, M.
    de la Haba-Rodriguez, J.
    Martrat, G.
    Perez-Escuredo, J.
    Alcala-Lopez, D.
    Sampayo-Cordero, M.
    Braga, S.
    Cortes, J.
    Llombart-Cussac, A.
    ESMO OPEN, 2024, 9 (09)
  • [50] Heterogeneity and prognostic characteristics of HER2-low breast cancer: A retrospective analysis of patients with HER2-negative metastatic breast cancer
    Lv, Huimin
    Yan, Min
    Zhang, Mengwei
    Niu, Limin
    Zeng, Huiai
    Sun, Huihui
    Zhao, Shengnan
    Wang, Jing
    CANCER RESEARCH, 2024, 84 (09)
12345